How Analysts Feel About Protalix Biotherapeutics Inc (de) (NYSEAMERICAN:PLX) After Increase in Sellers?

August 10, 2018 - By Russell Jones

Protalix BioTherapeutics, Inc. (NYSEAMERICAN:PLX) Logo

The stock of Protalix Biotherapeutics Inc (de) (NYSEAMERICAN:PLX) registered an increase of 2.4% in short interest. PLX’s total short interest was 5.33 million shares in August as published by FINRA. Its up 2.4% from 5.21 million shares, reported previously. With 356,300 shares average volume, it will take short sellers 15 days to cover their PLX’s short positions. The short interest to Protalix Biotherapeutics Inc (de)’s float is 4.29%.

It closed at $0.5 lastly. It is down 50.88% since August 10, 2017 and is downtrending. It has underperformed by 63.45% the S&P500.

Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company has market cap of $72.79 million. The firm offers taliglucerase alfa for injection, which is an enzyme replacement therapy for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease. It currently has negative earnings. The Company’s product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials to treat Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that is in phase II clinical trials to treat cystic fibrosis; and OPRX-106, an oral anti TNF product candidate, which is in Phase II clinical trial for the treatment of ulcerative colitis.

Protalix BioTherapeutics, Inc. (NYSEAMERICAN:PLX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.